Karin Agerman

1.5k total citations · 1 hit paper
18 papers, 1.2k citations indexed

About

Karin Agerman is a scholar working on Cellular and Molecular Neuroscience, Sensory Systems and Developmental Neuroscience. According to data from OpenAlex, Karin Agerman has authored 18 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cellular and Molecular Neuroscience, 6 papers in Sensory Systems and 6 papers in Developmental Neuroscience. Recurrent topics in Karin Agerman's work include Nerve injury and regeneration (7 papers), Neurogenesis and neuroplasticity mechanisms (5 papers) and Hearing, Cochlea, Tinnitus, Genetics (4 papers). Karin Agerman is often cited by papers focused on Nerve injury and regeneration (7 papers), Neurogenesis and neuroplasticity mechanisms (5 papers) and Hearing, Cochlea, Tinnitus, Genetics (4 papers). Karin Agerman collaborates with scholars based in Sweden, Italy and United States. Karin Agerman's co-authors include Patrik Ernfors, Eero Ċastrén, Panu Hendolin, Guilherme Lucas, Barbara Canlon, Mikko Sairanen, Annakaisa Haapasalo, Raquel Aloyz, Eija Koponen and Tommi Saarelainen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Neuroscience and Nature Neuroscience.

In The Last Decade

Karin Agerman

17 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects

2003 634 citations Tommi Saarelainen, Panu Hendolin et al. Journal of Neuroscience profile →

Peers

Countries citing papers authored by Karin Agerman

Since Specialization

Citations

This map shows the geographic impact of Karin Agerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Agerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Agerman more than expected).

Fields of papers citing papers by Karin Agerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Agerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Agerman. The network helps show where Karin Agerman may publish in the future.

Co-authorship network of co-authors of Karin Agerman

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Agerman. A scholar is included among the top collaborators of Karin Agerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Agerman. Karin Agerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	AAV-mediated gene therapy for focal epilepsy by expressing neuropeptide Y and Y2 receptor in rodent and non-human primate hippocampus 2025 ·Molecular Therapy ·(unknown), (unknown), Pernilla Fagergren, (unknown), Stefano Cattaneo, (unknown), (unknown), Michele Simonato, Karin Agerman, Mérab Kokaia, Lawrence Moon, Elizabeth Ramsburg	0
2	Gene Therapy Vector Encoding Neuropeptide Y and Its Receptor Y2 for Future Treatment of Epilepsy: Preclinical Data in Rats 2020 ·Frontiers in Molecular Neuroscience ·(unknown), (unknown), (unknown), (unknown), Stanislava Pankratova, (unknown), Karin Agerman, Mérab Kokaia, David P.D. Woldbye	17
3	Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β‐amyloid levels in the CNS 2014 ·Journal of Neurochemistry ·Biljana Georgievska, Susanne Gustavsson, Johan Lundkvist, Jan Neelissen, Susanna Eketjäll, (unknown), Tjerk Bueters, Karin Agerman, Anders Juréus, Samuel Svensson, Stefan von Berg, Johanna Fälting, Urban Lendahl	35
4	Elevated MARK2-Dependent Phosphorylation of Tau in Alzheimer's Disease 2013 ·Journal of Alzheimer s Disease ·(unknown), Di Wu, Harald Lund, Dan Sunnemark, Alexander Kvist, (unknown), (unknown), Lars Nilsson, Karin Agerman, Ulf Landegren, Masood Kamali‐Moghaddam	44
5	Decreased axonal transport rates in the Tg2576 APP transgenic mouse: improvement with the gamma‐secretase inhibitor MRK‐560 as detected by manganese‐enhanced MRI 2012 ·European Journal of Neuroscience ·Fuhua Wang, (unknown), Tomas Klason, Olof Gissberg, Anna Bogstedt, (unknown), (unknown), (unknown), Anders Andersson, Sandra A. G. Visser, Magnus Ivarsson, Mattias F. Lindberg, Karin Agerman, Johan Sandin	24
6	Evidence for dimeric BACE-mediated APP processing 2010 ·Biochemical and Biophysical Research Communications ·Shaobo Jin, Karin Agerman, Karin Kolmodin, (unknown), Camilla Dahlqvist, Anders Juréus, Gang Liu, Johanna Fälting, Stefan von Berg, Johan Lundkvist, Urban Lendahl	21
7	Identification of non-muscle myosin heavy chain as a substrate for Cdk5 and tool for drug screening 2009 ·Journal of Biomedical Science ·Anne Jämsä, Karin Agerman, Ann‐Cathrin Radesäter, (unknown), Jonas Malmström, (unknown), Gang Liu, Mervi Vasänge	6
8	Brain-derived neurotrophic factor selectively regulates dendritogenesis of parvalbumin-containing interneurons in the main olfactory bulb through the PLCγ pathway 2006 ·Journal of Neurobiology ·Paul Berghuis, Karin Agerman, Márton B. Dobszay, Liliana Minichiello, Tibor Harkany, Patrik Ernfors	43
9	Genetic evidence for selective neurotrophin 3 signalling through TrkC but not TrkB in vivo 2005 ·EMBO Reports ·(unknown), Karin Agerman, Frédéric Marmigère, Liliana Minichiello, Patrik Ernfors	12
10	Lingual deficits in neurotrophin double knockout mice 2004 ·Journal of Neurocytology ·Irina V. Nosrat, Karin Agerman, (unknown), Patrik Ernfors, Christopher A. Nosrat	22
11	Differential influence of BDNF and NT3 on the expression of calcium binding proteins and neuropeptide Y in vivo 2003 ·Neuroreport ·Karin Agerman, Patrik Ernfors	17
12	Neurotrophin-4 mediated TrkB activation reinforces morphine-induced analgesia 2003 ·Nature Neuroscience ·Guilherme Lucas, Panu Hendolin, Tibor Harkany, Karin Agerman, Gustavo Paratcha, Carl Holmgren, Yuri Zilberter, Mikko Sairanen, Liliana Minichiello, Eero Ċastrén, Patrik Ernfors	20
13	Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects breakdown → 2003 ·Journal of Neuroscience ·Tommi Saarelainen, Panu Hendolin, Guilherme Lucas, Eija Koponen, Mikko Sairanen, Ewen MacDonald, Karin Agerman, Annakaisa Haapasalo, Hiroyuki Nawa, Raquel Aloyz, Patrik Ernfors, Eero Ċastrén	634
14	BDNF gene replacement reveals multiple mechanisms for establishing neurotrophin specificity during sensory nervous system development 2003 ·Development ·Karin Agerman, Jens Hjerling‐Leffler, (unknown), Eric Scarfone, Barbara Canlon, Christopher A. Nosrat, Patrik Ernfors	89
15	Attenuation of a Caspase-3 Dependent Cell Death in NT4- and p75-Deficient Embryonic Sensory Neurons 2000 ·Molecular and Cellular Neuroscience ·Karin Agerman, Christel Baudet, Bengt T. Fundín, Christopher A. Willson, Patrik Ernfors	22
16	Complementary roles of neurotrophin 3 and a N- methyl- d -aspartate antagonist in the protection of noise and aminoglycoside-induced ototoxicity 2000 ·Proceedings of the National Academy of Sciences ·Maoli Duan, Karin Agerman, Patrik Ernfors, Barbara Canlon	140
17	Neurotrophins, NMDA receptors, and nitric oxide in development and protection of the auditory system. 1999 ·PubMed ·Karin Agerman, Barbara Canlon, Mao Li Duan, Patrik Ernfors	20
18	Pharmacological strategies for preventing cochlear damage induced by noise trauma. 1998 ·PubMed ·Barbara Canlon, Karin Agerman, R Dauman, Jean‐Luc Puel	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact